Sarepta-JPM-20240108.pdf

1、SAREPTA THERAPEUTICS,INC.2024.ALL RIGHTS RESERVED.1Sarepta Therapeutics,Inc.(NASDAQ:SRPT)JPMorgan Healthcare Conference San Francisco,CaliforniaJANUARY 8,2024DOUG INGRAMPresident and CEOSAREPTA THERAPEUTICS,INC.2024.ALL RIGHTS RESERVED.2FORWARD-LOOKING STATEMENTS This presentation contains forward-l

2、ooking statements.Any statements that are not statements of historical fact may be deemed to be forward-looking statements.Words such as“believe,”“anticipate,”“plan,”“expect,”“will,”“may,”“intend,”“prepare,”“look,”“potential,”“possible”and similar expressions are intended to identify forward-looking

3、 statements.These forward-looking statements include statements relating to future operations,financial performance and projections,including our expected financial results;potential solutions and market opportunities with our RNA technologies,gene therapy and gene editing;the potential benefits of

4、our technologies and scientific approaches;the potential benefits of PMO and PPMO;the potential of gene therapys applicability across disease;the potential of ELEVIDYS to benefit all patients living with Duchenne;our goal to become a life-transforming big biotech;and expected milestones and plans,in

5、cluding our understanding that,for ELEVIDYS,the FDA will evaluate a labeling expansion to the fullest extent possible based on a review of the data and will do so rapidly,our belief that our confirmatory trial for ELEVIDYS confirms its benefits and our accelerated approval should be converted to tra

6、ditional approval,announcing clinical data for SRP-5051 in 2024,and our other 2024 priorities,including moving our LGMD programs forward,including SRP-9003,driving innovation in manufacturing and other R&D goals.These forwardlooking statements involve risks and uncertainties,many of which are beyond